Clinical Trial Update: Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial exploring risk factors of immune checkpoint inhibitor–mediated liver, GI, endocrine, and skin toxicity across early-phase trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Gastric Cancer
• Hepatocellular Carcinoma
• Lung Cancer
• Melanoma
• Mesothelioma
• Renal Cell Carcinoma

Snippet

Sponsor: Western Sydney Local Health District | Conditions: Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN